1. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-273.
2. World Health Organization. Director-General's remarks at the media briefing on 2019-nCoV on 11 February 2020. http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020 (Accessed on July 9, 2021).
3. Our World in Data. Statistics and Research Coronavirus (COVID-19) Vaccinations. https://ourworldindata.org/covid-vaccinations (Accessed on July 9, 2021).
4. World Health Organization COVID-19 Weekly Epidemiological Update. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-july-2021 (Accessed on July 9, 2021).
5. Johns Hopkins Coronavirus Resource Center. COVID-19 dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). https://coronavirus.jhu.edu/map.html (Accessed on July 9, 2021).
6. World Health Organization. Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (Accessed on July 9, 2021).
7. World Health Organization. Therapeutics and COVID-19: living guideline. https://www.who.int/publications/i/item/therapeutics-and-covid-19-living-guideline (Accessed on July 9, 2021).
8. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at https://www.covid19treatmentguidelines.nih.gov/. (Accessed on July 9, 2021).
9. Wang C, Li W, Drabek D, et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020;11(1):2251.
10. Jahanshahlu L, Rezaei N. Monoclonal antibody as a potential anti-COVID-19. Biomed Pharmacother. 2020;129:110337.
11. Saphire EO, Schendel SL, Gunn BM, Milligan JC, Alter G. Antibody-mediated protection against Ebola virus. Nat Immunol. 2018;19(11):1169-1178.
12. Prabakaran P, Zhu Z, Xiao X, et al. Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther. 2009;9(3):355-368.
13. Kim C, Ryu DK, Lee J, et al. A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein. Nat Commun. 2021;12(1):288.
14. Joong Sik E, Michael I, Anca S-C, et al. Efficacy and safety of CT-P59 plus standard of care: a phase 2/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-moderate SARS-CoV-2 infection, 15 March 2021, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-296518/v1]. 2021.
15. Ministry of Food and Drug Safety. Approval of Regkirona(R) Inj., an antibody treatment for COVID-19. https://www.mfds.go.kr/brd/m_99/view.do?seq=45029&srchFr=&srchTo=&srchWord=&srchTp=0&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&Data_stts_gubun=C1009&page=2 (Accessed on July 9, 2021).
16. Ministry of Food and Drug Safety. Pharmaceutical Product Information: Regkirona(R) Inj. 960 mg (regdanvimab). https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetail?itemSeq=202101124 (Accessed on July 9, 2021).
17. European Medicines Agency. EMA issues advice on use of regdanvimab for treating COVID-19. https://www.ema.europa.eu/en/news/ema-issues-advice-use-regdanvimab-treating-covid-19 (Accessed on July 9, 2021).
18. Kim SB, Ryoo S, Huh K, et al. Revised Korean Society of Infectious Diseases/National Evidence-based Healthcarea Collaborating Agency Guidelines on the Treatment of Patients with COVID-19. Infection & Chemotherapy. 2021;53(1):166-219.
19. Clinical Trials Arena. Celltrion's Covid-19 drug regdanvimab meets Phase Ⅲ endpoints. https://www.clinicaltrialsarena.com/news/celltrion-regdanvimab-phaseiii-data/ (Accessed on July 7, 2021).
20. An EUA for bamlanivimab and etesevimab for COVID-19. Med Lett Drugs Ther. 2021;63(1621):49-50.
21. FDA. Fact sheet for health care providers. Emergency Use Authorization (EUA) of bamlanivimab and etesevimab. Available at: https://bit.ly/3qfS6DN. Accessed July 7, 2021.
22. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. The New England journal of medicine. 2021;384(3):238-251.
23. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368.
24. Gebhard C, Regitz-Zagrosek V, Neuhauser HK, Morgan R, Klein SL. Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020;11(1):29.
25. Klein SL, Dhakal S, Ursin RL, Deshpande S, Sandberg K, Mauvais-Jarvis F. Biological sex impacts COVID-19 outcomes. PLoS Pathog. 2020;16(6):e1008570.
26. Palaiodimos L, Kokkinidis DG, Li W, et al. Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York. Metabolism. 2020;108:154262.
27. Hurt AC, Wheatley AK. Neutralizing Antibody Therapeutics for COVID-19. Viruses. 2021;13(4).
28. Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014-1018.
29. Ryu DK, Song R, Kim M, et al. Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochem Biophys Res Commun. 2021;566:135-140.
30. Lam KW, Chow KW, Vo J, et al. Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome. The Journal of Infectious Diseases. 2020;222(8):1256-1264.
31. Fosbøl EL, Butt JH, Østergaard L, et al. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality. JAMA. 2020;324(2):168-177.
32. Gupta A, Madhavan MV, Poterucha TJ, et al. Association between antecedent statin use and decreased mortality in hospitalized patients with COVID-19. Nature communications. 2021;12(1):1-9.
33. Daniels LB, Sitapati AM, Zhang J, et al. Relation of Statin Use Prior to Admission to Severity and Recovery Among COVID-19 Inpatients. Am J Cardiol. 2020;136:149-155.
34. Osborne TF, Veigulis ZP, Arreola DM, Mahajan SM, Röösli E, Curtin CM. Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration. PLoS One. 2021;16(2):e0246825.
35. Chow JH, Khanna AK, Kethireddy S, et al. Aspirin Use Is Associated With Decreased Mechanical Ventilation, Intensive Care Unit Admission, and In-Hospital Mortality in Hospitalized Patients With Coronavirus Disease 2019. Anesth Analg. 2021;132(4):930-941.
36. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110-118.
37. Pastor‐Nieto M, Checa‐Díaz P, González‐Muñoz P, et al. Prior treatment with immunosuppressants among COVID‐19 inpatients at one hospital in Spain. J Eur Acad Dermatol Venereol. 2020.
38. Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442-447.